JTJanne J. Turunen

Janne J. Turunen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janne J. Turunen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations

    by Kalyan Dulla, Ralph Slijkerman, Hester C. van Diepen, Silvia Albert, Margo Dona, Wouter Beumer, Janne J. Turunen, Hee Lam Chan, Iris A. Schulkens, Lars Vorthoren, et al.


  • Open Access

    581. Correcting Exon Skipping Splicing Defects in BTK RNA by Using Bifunctional Oligonucleotides

    by C.I. Edvard Smith, Burcu Bestas, Janne J. Turunen, Jesper Wengel

  • Open Access

    Splice-Correction Strategies for Treatment of X-Linked Agammaglobulinemia

    by Burcu Bestas, Janne J. Turunen, K. Emelie M. Blomberg, Qing Wang, Robert Månsson, Samir EL Andaloussi, Anna Berglöf, C. I. Edvard Smith

    X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease caused by mutations in the gene coding for Bruton’s tyrosine kinase (BTK). Deficiency of BTK leads to a developmental block in B cell differentiation; hence, the patients essentially lack antibody-producing plasma cells and are susceptible to various infections. A substantial portion of the mutations in BTK results in splicing defects, consequently preventing the formation of protein-coding mRNA. Antisense oligonucleotides (ASOs) are therapeutic compounds that have the ability to modulate pre-mRNA splicing and alter gene expression. The potential of ASOs has been exploited for a few severe diseases, both in pre-clinical and clinical studies. Recently, advances have also been made in using ASOs as a personalized therapy for XLA. Splice-correction of BTK has been shown to be feasible for different mutations in vitro, and a recent proof-of-concept study demonstrated the feasibility of correcting splicing and restoring BTK both ex vivo and in vivo in a humanized bacterial artificial chromosome (BAC)-transgenic mouse model. This review summarizes the advances in splice correction, as a personalized medicine for XLA, and outlines the promises and challenges of using this technology as a curative long-term treatment option.


  • RNA Ligation

    by Janne J. Turunen, Liudmila V. Pavlova, Martin Hengesbach, Mark Helm, Sabine Müller, Roland K. Hartmann, Mikko J. Frilander


  • Open Access

    Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression

    by Sofia Stenler, Oscar Pb Wiklander, Maria Badal-Tejedor, Janne Turunen, Joel Z Nordin, David Hallengärd, Britta Wahren, Samir EL Andaloussi, Mark W Rutland, Ci Edvard Smith, et al.


  • Agammaglobulinemia: causative mutations and their implications for novel therapies

    by Anna Berglöf, Janne J Turunen, Olof Gissberg, Burcu Bestas, K Emelie M Blomberg, Ci Edvard Smith

    Agammaglobulinemias are primary (inherited) immunodeficiencies characterized by the lack of functional B-cells and antibodies, and are caused by mutations in genes encoding components of the pre-B-cell or B-cell receptor, or their signaling pathways. The known genetic defects do not account for all agammaglobulinemic patients, suggesting that novel mutations underlying the disease remain to be found. While efficient, the current life-maintaining therapy with immunoglobulins and antibiotics is non-curative, prompting research into alternative treatment strategies that aim at rescuing the expression of the affected protein, thus giving rise to functional B-cells. These include gene therapy, which could be used to correct the defective gene or replace it with a functional copy. For a number of genetic defects, another alternative is to modulate the splicing of the affected transcripts. While these technologies are not yet ready for clinical trials in agammaglobulinemia, advances in genomic targeting are likely to make this option viable in the near future.


  • Open Access

    HnRNPH1/H2, U1 snRNP, and U11 snRNP cooperate to regulate the stability of the U11-48K pre-mRNA

    by Janne J. Turunen, Bhupendra Verma, Tuula A. Nyman, Mikko J. Frilander

    Alternative splicing (AS) is a major contributor to proteome diversity, but it also regulates gene expression by introducing premature termination codons (PTCs) that destabilize transcripts, typically via the nonsense-mediated decay (NMD) pathway. Such AS events often take place within long, conserved sequence elements, particularly in genes encoding various RNA binding proteins. AS-NMD is often activated by the protein encoded by the same gene, leading to a self-regulating feedback loop that maintains constant protein levels. However, cross-regulation between different RNA binding proteins is also common, giving rise to finely tuned regulatory networks. Recently, we described a feedback mechanism regulating two protein components of the U12-dependent spliceosome (U11-48K and U11/U12-65K) through a highly conserved sequence element. These elements contain a U11 snRNP-binding splicing enhancer (USSE), which, through the U11 snRNP, activates an upstream U2-type 3′ss, resulting in the degradation of the U11-48K mRNA by AS-NMD. Through phylogenetic analysis, we now identify a G-rich sequence element that is conserved in fishes as well as mammals. We show that this element binds hnRNPF/H proteins in vitro. Knockdown of hnRNPH1/H2 or mutations in the G-run both lead to enhanced activation of the 3′ss in vivo, suggesting that hnRNPH1/H2 proteins counteract the 3′ss activation. Furthermore, we provide evidence that U1 binding immediately downstream from the G-run similarly counteracts the U11-mediated activation of the alternative 3′ss. Thus, our results elucidate the mechanism in which snRNPs from both spliceosomes together with hnRNPH1/H2 proteins regulate the recognition and activation of the highly conserved alternative splice sites within the U11-48K pre-mRNA.


  • Open Access

    The significant other: splicing by the minor spliceosome

    by Janne J. Turunen, Elina H. Niemelä, Bhupendra Verma, Mikko J. Frilander

    The removal of non‐coding sequences, introns, from the mRNA precursors is an essential step in eukaryotic gene expression. U12‐type introns are a minor subgroup of introns, distinct from the major or U2‐type introns. U12‐type introns are present in most eukaryotes but only account for less than 0.5% of all introns in any given genome. They are processed by a specific U12‐dependent spliceosome, which is similar to, but distinct from, the major spliceosome. U12‐type introns are spliced somewhat less efficiently than the major introns, and it is believed that this limits the expression of the genes containing such introns. Recent findings on the role of U12‐dependent splicing in development and human disease have shown that it can also affect multiple cellular processes not directly related to the functions of the host genes of U12‐type introns. At the same time, advances in understanding the regulation and phylogenetic distribution of the minor spliceosome are starting to shed light on how the U12‐type introns and the minor spliceosome may have evolved. WIREs RNA 2013, 4:61–76. doi: 10.1002/wrna.1141This article is categorized under: RNA Processing > Splicing Mechanisms


  • An Ancient Mechanism for Splicing Control: U11 snRNP as an Activator of Alternative Splicing

    by Jens Verbeeren, Elina H. Niemelä, Janne J. Turunen, Cindy L. Will, Janne J. Ravantti, Reinhard Lührmann, Mikko J. Frilander


  • Minor spliceosome components are predominantly localized in the nucleus

    by Heli K. J. Pessa, Cindy L. Will, Xiaojuan Meng, Claudia Schneider, Nicholas J. Watkins, Nina Perälä, Mariann Nymark, Janne J. Turunen, Reinhard Lührmann, Mikko J. Frilander

    Recently, it has been reported that there is a differential subcellular distribution of components of the minor U12-dependent and major U2-dependent spliceosome, and further that the minor spliceosome functions in the cytoplasm. To study the subcellular localization of the snRNA components of both the major and minor spliceosomes, we performedin situhybridizations with mouse tissues and human cells. In both cases, all spliceosomal snRNAs were nearly exclusively detected in the nucleus, and the minor U11 and U12 snRNAs were further shown to colocalize with U4 and U2, respectively, in human cells. Additionally, we examined the distribution of several spliceosomal snRNAs and proteins in nuclear and cytoplasmic fractions isolated from human cells. These studies revealed an identical subcellular distribution of components of both the U12- and U2-dependent spliceosomes. Thus, our data, combined with several earlier publications, establish that, like the major spliceosome, components of the U12-dependent spliceosome are localized predominantly in the nucleus.